İrem ŞAHİNOĞLU, Mustafa Serhat ŞAHİNOĞLU, Sevil ALKAN, Derya Çelebi AYDIN

Biyolojik Tedaviler ve Tüberküloz: Bir Derleme Çalışması

Tüberküloz (TB); özellikle akciğer tutulumu ile giden ancak neredeyse tüm organları tutabilen bakteriyel bir hastalıktır. Eski zamanlardan beri bilinen bu hastalık, özellikle immunsüpresif tedavi alan hasta sayılarının artması ile tekrar gündeme gelmiştir. Günümüzde oldukça popüler tedavi seçeneklerinden olan biyolojik ilaçlar; hematolojik, otoimmün hatta malign hastalıkların tedavisinde devrim yaratmıştır. Bu ilaç sınıfı arasında monoklonal antikorlar (adalimumab, infliximab, golimumab) ve antikor fragmanı (certolizumab) sayılabilir. Tümör nekroz faktör (TNF) alfa inhibitörleri gibi biyolojik ajanlarla tedavinin artmış TB riski ile ilişkisi iyi bilinmektedir. Anti-TNF tedavisi planlanan hastaların tıbbi geçmişleri ayrıntılı bir şekilde sorgulanmalı, ayrıntılı muayene edilmeli ve akciğer grafisi çekilmelidir. Aktif TB enfeksiyonu veya sekel TB enfeksiyonu açısından değerlendirilmelidir. Bu derleme yazısında mevcut bilimsel literatürün gözden geçirilmesi amaçlanmıştır.

Anahtar Kelimeler:

Biyolojik terapi, Tüberküloz, Tümör nekroz faktör alfa

Biological Therapies and Tuberculosis: A Review Study

Tuberculosis (TB) infection is a bacterial disease that can involve almost all organs, especially with lung involvement. This disease, which has been known since ancient times, has come to the fore again, especially with the increase in the number of patients receiving immunosuppressive therapy. Biological drugs, which are very popular treatment options today, have revolutionized the treatment of some hematological and autoimmune diseases. This class of drugs includes monoclonal antibodies (adalimumab, infliximab, golimumab) and antibody fragment (certolizumab). Treatment with biological agents such as tumor necrosis factor (TNF) alpha inhibitors is known to be associated with an increased risk of TB. The medical history of the patients who are planned for anti-TNF treatment should be questioned in detail, examined in detail, and chest X-ray should be taken. It should be evaluated for active TB infection or sequelae. TB infection.In this review article, it is aimed to review the current scientific literature.

Keywords:

Biological therapy, Tuberculosis, Tumor necrosis factor alpha,

PDF

___

Baddley JW, Cantini F, Goletti D, Gómez-Reino JJ, Mylonakis E, San-Juan R, Fernández-Ruiz M, Torre-Cisneros J. 2018. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents. Clin Microbiol Infect, 24(Suppl 2): S10-S20.
Caporali R, Crepaldi G, Codullo V, Benaglio F, Monti S, Todoerti M, Montecucco C. 2018. 20 years of experience with tumour necrosis factor inhibitors: what have we learned? Rheumatology, 57(Suppl 7): vii5–vii10. doi.org/10.1093/rheumatology/key059.
Dobler CC. 2016. Biologic agents and tuberculosis. Microbiol Spectrum, 4(6), 10.1128/microbiolspec.TNMI7-0026-2016. doi.org/10.1128/microbiolspec.TNMI7-0026-2016.
Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, B S R B R Control Centre Consortium, Symmons DP, BSR Biologics Register. 2010. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis, 69(3): 522–528. doi.org/10.1136/ard.2009.118935.
Furin J, Cox H, Pai M. 2019. Tuberculosis. Lancet, 393(10181): 1642–1656. doi.org/10.1016/S0140-6736(19)30308-3.
Flynn JL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K, Lowenstein CJ, et al. 1995. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity, 2(6): 561–572. doi.org/10.1016/1074-7613(95)90001-2.
Godfrey MS, Friedman LN. 2019. Tuberculosis and Biologic Therapies: Anti-Tumor Necrosis Factor-α and Beyond. Clinics Chest Med, 40(4): 721–739. doi.org/10.1016/j.ccm.2019.07.003.
Goletti D, Petrone L, Ippolito G, Niccoli L, Nannini C, Cantini F. 2018. Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs. Expert Rev Anti-infective Therapy, 16(6): 501–512. doi.org/10.1080/14787210.2018.1483238.
Ho CTK, Mok CC. 2015. Consensus statements on the screening of latent tuberculosis infection prior to the use of biological agents for rheumatic diseases in Hong Kong. Hong Kong Bull Rheum Dis, 15: 1-6.
Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T. 2010. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology, 49(7): 1215–1228. doi.org/10.1093/rheumatology/keq031.
Kanbay A, Yakar Hİ. 2021. Biyolojik tedaviler ve tüberküloza yaklaşım. Karadağ AS, editör. Türkiye Klinikleri, Dermatolojide Biyolojik Tedaviler, 1. Baskı, Ankara, Türkiye, ss. 12-16.
Kaufmann SH. 2002. Protection against tuberculosis: cytokines, T cells, and macrophages. Ann Rheum Dis, 61(Suppl 2): ii54–ii58. doi.org/10.1136/ard.61.suppl_2.ii54.
Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. 2001. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. The New England J Med, 345(15): 1098–1104. doi.org/10.1056/NEJMoa011110.
Lam S, Mok CC. 2021. The Hong Kong Society of Rheumatology Biologics Registry: updated report. J Clin Rheumatol Immunol, 21: 60-63.
Manca C, Tsenova L, Bergtold A, Freeman S, Tovey M, Musser JM, Barry CE, 3rd, Freedman VH, Kaplan G. 2001. Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-alpha /beta. Proc Natl Acad Sci U S A, 98(10): 5752–5757. doi.org/10.1073/pnas.091096998
Miller EA, Ernst JD. 2008. Illuminating the black box of TNF action in tuberculous granulomas. Immunity, 29(2): 175–177. doi.org/10.1016/j.immuni.2008.07.003.
Mitoma H, Horiuchi T, Tsukamoto H, Ueda N. 2018. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists. Cytokine, 101: 56–63. doi.org/10.1016/j.cyto.2016.08.014.
Mok CC, Tam LS, Chan TH, Lee GK, Li EK, Hong Kong Society of Rheumatology. 2011. Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology. Clinical Rheumatol, 30(3): 303–312. doi.org/10.1007/s10067-010-1596-y.
Nisar MK, Rafiq A, Östör AJ. 2015. Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom. Clinical Rheumatol, 34(12): 2141–2145. doi.org/10.1007/s10067-015-3099-3.
Parigi S, Licari A, Manti S, Marseglia GL, Tosca MA, Miraglia Del Giudice M, et al. 2020. Tuberculosis and TNF-α inhibitors in children: how to manage a fine balance. Acta Biomed, 91(11-S): e2020009. doi.org/10.23750/abm.v91i11-S.10311.
Robert M, Miossec P. 2021. Reactivation of latent tuberculosis with TNF inhibitors: critical role of the beta 2 chain of the IL-12 receptor. Cellular Molec Immun, 18(7): 1644–1651. doi.org/10.1038/s41423-021-00694-9.
Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban et al. Research Axed on Tolerance of Biotherapies Group. 2009. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum, 60(7): 1884–1894. doi.org/10.1002/art.24632.
URL 1. WHO | World Health Organization. Tuberculosis. Avaliable from: https://www.who.int/health-topics/tuberculosis#tab=tab_1 (accessed date: March 23, 2022).
URL 2. Global tuberculosis report 2020. ISBN 978-92-4-001313-1 (electronic version) (accessed date: March 23, 2022).
URL 3. T.C. Sağlık Bakanlığı Türkiye Halk Sağlığı Kurumu. Anti-TNF Kullanan Hastalarda Tüberküloz Rehberi. https://www.romatoloji.org/Dokumanlar/Site/ATKHTR.pdf (accessed date: March 23, 2022).
URL 4. WHO consolidated guidelines on tuberculosis (Module 1: Prevention) Tuberculosis preventive treatment. Geneva: World Health Organization. 2020. https://www.who.int/publications/i/ item/who-consolidated-guidelines-on-tuberculosis-module-1- prevention-tuberculosis-preventive-treatment (accessed date: March 23, 2022).
Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. 2004. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis, 38(9): 1261–1265. doi.org/10.1086/383317.
Winthrop KL, Baxter R, Liu L, Varley CD, Curtis JR, Baddley JW, et al. 2013. Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis, 72(1): 37–42. doi.org/10.1136/annrheumdis-2011-200690.